Amesite Reports 63% Revenue Growth from NurseMagic™ Enterprise; Announces Launch of AI-Powered Government Form-Fill Automation to Reduce Reporting Burden
Rhea-AI Summary
Amesite (NASDAQ: AMST), an AI-powered enterprise solutions developer, reported 63% revenue growth for its NurseMagic™ platform following the July 14, 2025 launch of its census-based Enterprise subscription model. The company announced that Enterprise sales have surpassed B2C sales, driven by post-acute care providers seeking scalable compliance solutions.
Amesite also launched an AI-powered automated form fill solution for government forms, specifically targeting the upcoming Centers for Medicare & Medicaid Services (CMS) mandate for Hospice Outcomes and Patient Evaluation (HOPE) assessment. The solution aims to help healthcare organizations auto-populate complex forms, reduce administrative time, and ensure full reimbursements in a market growing at a CAGR of 8%.
Positive
- Revenue growth of 63% for NurseMagic platform
- Enterprise sales surpassing B2C sales, indicating successful business model transition
- Launch of AI-powered HOPE automation solution addressing upcoming regulatory requirements
- Operating in post-acute care market with 8% CAGR growth rate
Negative
- None.
News Market Reaction 15 Alerts
On the day this news was published, AMST gained 44.40%, reflecting a significant positive market reaction. Argus tracked a peak move of +117.8% during that session. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $6M to the company's valuation, bringing the market cap to $19M at that time. Trading volume was exceptionally heavy at 3181.1x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
DETROIT, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Amesite Inc. (NASDAQ: AMST), a leading developer of AI-powered enterprise solutions, today announced
"We’re no longer just selling to employees – we’re selling to serve every patient in the system and help organizations leverage AI technology as a true competitive advantage," said Brandon Owens, VP of Sales at Amesite. "That changes the game. The total addressable market is exponentially larger, and our pricing reflects the performance of our solution. Customers are choosing NurseMagic™ Enterprise to scale operations without adding staff, addressing one of the greatest costs in healthcare."
The announcement comes as the Centers for Medicare & Medicaid Services (CMS) prepares to mandate the Hospice Outcomes and Patient Evaluation (HOPE) assessment this October – a regulatory overhaul expected to significantly increase documentation burden per patient and strain already thin hospice staffing cohort. Amesite’s AI-powered HOPE automation solution, within NurseMagic™ Enterprise, is designed to enable organizations to auto-populate complex forms, cut administrative time, and assure full reimbursements.
"The government’s scrutiny of documentation is intensifying, and many organizations are unprepared," said Kalie Wortinger, Senior Engineering Manager at Amesite. "With the HOPE requirement looming, providers are seeking a solution that enables compliant, reimbursable submission of documentation. NurseMagic™ Enterprise has modular intelligence that enables our customers to document compliantly, and to be fully reimbursed for the crucial work they do."
"We’ve taken an entirely different approach from traditional EMR vendors," said Dr. Ann Marie Sastry, CEO of Amesite. "Our platform reimagines how post-acute care organizations handle regulatory requirements, enabling them to leverage our AI-powered tools to scale operations without adding staff. We specifically designed our solution to be an essential edge for customers, in a highly competitive, and demographically inevitable, market."
The post-acute care market is growing faster than the acute care market at a CAGR of
Post-acute care owners can book a demo to learn more about NurseMagic™’s HOPE solution here.
About Amesite Inc.
Amesite (NASDAQ: AMST) is an AI-driven company with an immediate aim to transform the
Forward-Looking Statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning the Company, the Company's planned online machine learning platform, the Company's business plans, any future commercialization of the Company's online learning solutions, potential customers, business objectives and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement. Risks facing the Company and its planned platform are set forth in the Company's filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations
FAQ
What was Amesite's (NASDAQ: AMST) revenue growth for NurseMagic in 2025?
What is Amesite's new AI-powered solution for healthcare providers?
How is Amesite addressing the upcoming CMS HOPE mandate?
What is the growth rate of the post-acute care market where Amesite operates?
How has Amesite's business model evolved with NurseMagic?
